Home / Transcripts / CeriBell, Inc. (CBLL) · November 3, 2026

CeriBell, Inc. (CBLL) Earnings Call Transcript

November 3, 2026

NASDAQ US Health Care Health Care Equipment and Supplies earnings 42 min

Earnings Call Speaker Segments

Brian Johnston executive
#1

Thanks for joining us this afternoon. On the line with me from CeriBell are Jane Chao, our Co-Founder and Chief Executive Officer, along with Scott Blumberg, our Chief Financial Officer. Earlier today, CeriBell put out a press release with the financial results for the quarter that closed on September 30, 2026. You can find a copy of that release in the Investor Relations section of the company's website. Before we get started, I want to remind everyone that during this call, management will be making remarks that include forward-looking statements as defined under federal securities laws, and those remarks are being made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements on this call relating to expectations or predictions about future events, results, or performance qualify as forward-looking statements. Such statements carry material risks and uncertainties that could cause actual results or events to differ materially from what those forward-looking statements anticipate or imply. As a result, you should not rely unduly on them. For a list and description of the risks and uncertainties tied to our business, please see the Risk Factors section of our public filings with the Securities and Exchange Commission, including our annual report on Form 10-K filed with the SEC on February 24, 2026, and our quarterly report on Form 10-Q covering the quarter ended September 30, 2026. This conference call includes time-sensitive information that is accurate only as of the live broadcast today, November 3, 2026. Except as required by law, CeriBell disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether as a result of new information, future events, or otherwise. With that, I'll hand the call over to Jane.

Xingjuan Chao executive
#2

Good afternoon, and thank you for joining us on our third quarter 2026 earnings call. For CeriBell, Q3 proved to be yet another robust quarter, posting revenue of $29.3 million, which represents growth of roughly 30% compared with the same period a year earlier. That growth was driven by accomplishments across both of our primary revenue sources: more accounts adopting our offering and greater penetration inside our existing installed base. In Q3, we brought a record 35 hospitals into our account base, which lifted our total to 747 active accounts. This demonstrates how our account acquisition team has continued to mature and perform strongly. We maintain a substantial pipeline of accounts that have not yet launched, and we anticipate these will drive ongoing growth over the coming quarters. Headband utilization likewise reached an all-time high during Q3. On a year-over-year basis, usage for each account rose by a double-digit percentage — the strongest pace since we went public. That continues the momentum from Q2 and shows our playbook being put into action: engaging providers, growing within departments and driving protocolization across patient populations. Department expansion, in particular, is speeding up. So far in 2026 we have moved into a greater number of departments than we did across all of 2025, and we anticipate sustaining that rate; collectively, these outcomes offer further proof that our core seizure business is a lasting growth engine. Beyond that core strategy, we are also advancing on a number of key initiatives introduced this year to add to organic growth. To begin with, encouraging signals are coming from the strategic account management team we recently set up. By working directly with regional health systems at the top levels, we think this team is going to create fresh paths for growing accounts. These opportunities do take longer to close because of the sales cycles involved, but we're still seeing bigger deals move forward through our pipeline. Next, our strategy for VA and DoD continues to be a growth driver, and engagement is strong at both government health systems; during Q3 we obtained a commitment to expand further within VA, which ought to have a positive effect on active accounts and revenue growth over the quarters ahead. Lastly, interest in our neonate product is still strong, with pipeline development continuing and NICUs being activated in both new and existing accounts. Because every one of those key 2026 initiatives is showing strong signal, we're in a good position to keep driving revenue growth as we head into 2027. At this point I'd like to focus on delirium, which is our next big growth opportunity. This week, earlier on, we announced that our delirium monitoring solution is launching; not long ago we wrapped up a commercial pilot that assessed clinical utility and adoption with customers who were already using our seizure platform. Six months in, I'm glad to say the pilot has delivered meaningful impact—both by improving patient care and by confirming that our delirium monitoring solution works as a new revenue stream. The encouraging results we reported last quarter have kept up across a larger number of accounts. According to customers, clinical decision-making has gotten better and users are having good experiences. In numerous instances, our solution makes long-term monitoring possible for the very first time, and that stands out particularly with patients who are hard to assess. To illustrate the clinical significance of this, I'd like to share a case involving a woman in her early 30s suffering from sepsis. She had been admitted to the ICU of a 150-bed community hospital and primary stroke center. Because she was not at her neurological baseline, the care team applied a CeriBell headband to determine what was happening. The system returned a seizure negative and delirium positive result, which provided the team with immediate, objective guidance to focus on delirium management. Before this site adopted CeriBell's delirium monitoring solution, its delirium assessments had been inconsistent and seldom part of routine discussion. In this case, the result got nurses, physicians and pharmacists to jointly review possible contributing factors. With a septic patient, antibiotics weren't always called into question; this time, the team pinpointed cefepime—a commonly used antibiotic with neurotoxicity—as a possible contributor to the patient's delirium and chose to switch the patient to a different antibiotic drug. Beyond that initial delirium detection, CeriBell also made continuous monitoring possible after the antibiotic adjustment. The delirium trend started to decline. By day 3, the patient was no longer delirium positive. According to the team, objective diagnosis and trend monitoring provided a clear justification for reconsidering the infection treatment choice, along with the information required to establish that their approach had succeeded in resolving delirium. Clinicians elsewhere have reported similar outcomes, which confirms the worth of what we offer and encourages repeat use. CeriBell assists the care team in identifying delirium rapidly while creating management options that span from medication reviews to nonpharmacologic interventions. As such experiences accumulate, we anticipate broader adoption and deepening usage. In the pilot, the clinical usefulness of our system converted directly into commercial results. We are observing a substantial rise in headband use among existing customers who later rolled out our delirium monitoring solution. Growth ahead should stem from broadening the patient population, the substantial clinical value of tracking delirium and seizures at the same time, and customer engagement. That effect has held up over time—our first customers have logged no less than 120 days of use since launch. Notably, the usage gains appeared prior to our NTAP taking effect on October 1, which points to clinical utility as the main force behind them. As we kept honing how we launch, we've observed still bigger usage gains in accounts brought on board more recently. Given these findings, we think lowering adoption hurdles will enable us to generate meaningful commercial impact. As we get ready to go commercial, we're providing our delirium monitoring solution to CeriBell customers as a software upgrade with no added cost to their subscription. What we do require is that interested customers work with us through program commitments, which we see as essential for getting the most clinical utility and keeping usage sustained. As an example, we request that customers make sure we're able to train over 80% of their nurses and physicians during the launch process and that we agree on KPIs for delirium monitoring and management. We're also working alongside customers to confirm they have sufficient recorder capacity for the greater patient volume and for monitoring periods that may run longer when delirium is involved. That way, our customers are positioned to succeed with high-quality launches. Offering the product with no added subscription fee goes a long way toward avoiding the drawn-out sales and contracting work that might otherwise slow adoption; even so, the launch process we’ve seen create impact calls for careful execution over time. Bringing in a technology this disruptive means customers must evolve how they practice and work closely alongside our team; we anticipate that many accounts will move quickly to adopt our delirium monitoring solution, though conversion at broad scale will happen gradually. Our belief is that this strategy will ultimately drive the largest durable revenue effect resulting from increased clinical use, and that use is the primary measure of revenue contribution for our delirium monitoring solution. As we move from pilot to full launch, we will continue to monitor the utilization impact. In our 2027 financial guidance, we plan to provide a more detailed picture of the anticipated revenue effect associated with this greenfield market opportunity. Notably, this strategy will be executed by our current sales organization, which gives us more leverage from our commercial infrastructure. We are also eager to share updates on how these aspects of our delirium monitoring solutions influence our financial performance.

Xingjuan Chao executive
#3

We have two main pillars supporting how we approach product development: making our algorithms smarter so they produce stronger clinical insights, and pushing hardware innovation forward so those algorithms are supported. A great illustration of that first pillar is our delirium monitoring solution, since it widens the patient groups we can reach. Beyond that, we keep building additional algorithms that make our product more clinically useful for the physicians we serve. Two recent examples are algorithms cleared through FDA 510(k) for quantitative EEG trending and for Amplitude-Integrated EEG Analysis. Quantitative EEG, or qEEG, adds 3 capabilities: alpha-delta ratio, relative alpha trending, and burst suppression monitoring. Clinicians frequently rely on such trends when treating complicated neurological conditions, using them to help judge brain distress, diminished blood flow, or over-sedation. Even so, for the clinician at the bedside these outputs have stayed mostly out of reach, despite how relevant they are clinically. That is what our algorithm will change. We give customers deeper insight into what is happening in a patient's brain. This meaningfully boosts the value we offer to bedside users and neurologists alike. A cloud-based software update will deliver these features next year. At the same time, our LVO stroke clinical program keeps advancing, and we are actively looking into further opportunities for algorithm development to bring onto our platform. Taken together, these efforts should generate more clinical impact and wider market expansion over the longer term. We look forward to providing updates on those potential opportunities down the road. We are very excited about what we have achieved in algorithm development, but that is not where we stop. The second prong of our strategy centers on making our hardware platform better. As mentioned before, we deliberately built our new hardware platform so it could expand functionality and incorporate additional modalities, all in service of our vision of EEG as a vital sign. We are now delighted to reveal the product name for this platform: Omni. Omni, which means everything in Latin, captures exactly what we envision for the future. For the first time, hospitals can access point-of-care EEG's speed while retaining conventional EEG's comprehensiveness, enhanced by eight FDA-cleared algorithms of ours that watch the brain for seizure, status epilepticus, delirium and additional brain stress indicators, all within one platform, Omni. Through Omni, we're introducing video, multi-day continuous monitoring capability, EKG compatibility and a parasagittal add-on delivering full montage coverage when needed; this delivers conventional EEG's core features without sacrificing point-of-care EEG's ease of use, speed and accessibility. Even more crucial to our vision, the system was designed to run each of our algorithms, allowing brain monitoring across multiple disease states. This single design serves the needs of clinicians at the bedside as well as urologists. In our view, the tool is truly one of a kind. A limited market release of Omni starts this quarter, and we anticipate launching the product in 2027. As launch approaches, we'll provide more details. In hindsight, our vision of EEG as a new vital sign has clearly moved beyond theory. With our commercial footprint expanded and 9 FDA clearances secured during the past 18 months, we're now nearer than ever to bringing that vision to market. We see 2027 as a pivotal year. Seizure detection will act as a durable base business. Each of account acquisition and utilization is expanding independently, and they reinforce one another. Improvements we've made to hardware and software will broaden our category leadership. Our delivery and monitoring solution is set to launch fully; and we now hold stronger confidence in our capacity to unify the whole of our innovation within one product platform, Omni. An inflection point has been reached at CeriBell. Following years of investment and growth, we're eager to start our new chapter while continuing to deliver unique value to our customers and the patients in their care. Having said that, I'll now hand the call to Scott Blumberg, our CFO, who will review the third quarter results and 2026 guidance.

Scott Blumberg executive
#4

Appreciate that, Jane, and hello everyone this afternoon. Total revenue for Q3 2026, as Jane mentioned, was $29.3 million — an increase of about 30% compared with $22.6 million in Q3 2025, and 4% higher quarter over quarter. Driving that improvement were primarily the strong results of our same-store growth strategy and wider uptake of the CeriBell system across both new and existing accounts. Products revenue in Q3 2026 was $22.2 million, up 31% versus $17 million in Q3 2025. Per-account usage during Q3 rose by a double-digit percentage — the strongest figure since our IPO. For the third quarter of 2026, subscription revenue came in at $7.1 million, which represents a 28% increase over the $5.6 million recorded in the third quarter of 2025. We ended Q3 with 747 hospitals in our active account base, adding 35 accounts during the quarter. Gross margin in Q3 2026 reached 90%, compared with 88% a year earlier, demonstrating our capacity to continue producing exceptional gross profit that supports our growth-focused investments. In light of the current tariff policy and where our inventory stands today, we anticipate that margins will remain in the high 80% range moving forward. Operating expenses totaled $46.9 million in the third quarter of 2026, a 36% rise from $34.6 million in the third quarter of 2025. Stock-based compensation, which is noncash, came to $7.1 million during the third quarter of 2026, versus $3.3 million a year earlier. Our sales and marketing expense reached $25 million in the third quarter, reflecting sustained investment in the commercial organization — among those investments, spending on our CAM infrastructure as we prepare to launch the delirium monitoring solution. Third-quarter G&A expense of $14.5 million includes costs tied to our ongoing IP litigation, which amounted to $1.1 million. Litigation-related activities should stay low in Q4, though depending on how our current ITC proceeding turns out, we may end up paying $2.9 million in deferred legal fees. Third-quarter R&D spending came to $7.4 million, which shows the investments we've been putting into our platform — our next-generation hardware, work on algorithms, and clinical studies among them. That above-trend rise in R&D outlays has produced substantial effects, such as speeding up the commercial launch of our delirium monitoring solution as well as Omni. Net interest and other expense in the third quarter totaled $803,000; that figure includes $1.5 million tied to extinguishing our prior debt facility, partly offset by interest income from cash and marketable securities. Given the new revolver first debt structure, we anticipate interest expense will fall considerably down the road, to under $1 million per year. For the third quarter of 2026, our net loss came to $21.4 million, which works out to $0.55 per share in losses. That compares with a loss of $13.5 million, or $0.37 per share, in the third quarter of 2025. When we calculated loss per share for Q3 2026, the weighted average share count we used was 38.5 million shares. Adjusted EBITDA means our net loss before interest, taxes, depreciation and amortization expense; on top of that, it excludes noncash stock-based compensation expenses, legal expenses tied to our ongoing IP litigation, and the loss from extinguishment of our prior credit facility. For the third quarter of 2026, our adjusted EBITDA loss was $12.1 million. In the third quarter of 2025, that figure was $9.2 million. This reflects the strategy we continue to follow: deliberately plowing gross profits from a growing revenue base back into the business as we chase long-term growth opportunities. As of September 30, 2026, cash, cash equivalents and marketable securities totaled $117.5 million. Reaching cash flow breakeven remains our goal, and the cash on hand, the strength of our balance sheet and our strong gross margin profile give us great confidence in our ability to get there. Now let me turn to our outlook for 2026. Looking ahead to the full year 2026, we expect revenue to land between $115 million and $117 million, compared with our earlier outlook of $114 million to $117 million — that represents year-over-year growth of 29% to 31% versus 2025. The revised guidance captures the momentum we're seeing in our core business, driven by gains on both fronts: new accounts coming on board and increased usage among our existing account base. Note that this range does not factor in any material contribution from our neonate, pediatric, or delirium products, which we anticipate will begin contributing to revenue more substantially in 2027. With that, I'll turn the call back over to Jane.

Xingjuan Chao executive
#5

Thanks, Scott, and I appreciate everyone taking the time to be with us today. The third quarter strengthened how confident we are in the path we're on. Seizure, our core business, gives us a solid and predictable foundation. The pilot we ran for delirium came through successfully, and as we move toward a full commercial launch, we're quite optimistic. We've stayed dedicated to putting money into innovation — that covers several new algorithms as well as our Omni platform — and this has positioned us for a pivotal 2027. Within our core seizure market, penetration sits below 4%, and that figure shows just how much runway remains in front of us. On top of that, we're moving into fresh greenfield markets with urgency and a sense of purpose. Making EEG a new vital sign is still our North Star, and the strides we made during Q3 give us every reason to push harder still. Thanks once more for being on the call. At this point I'll hand things to the operator for the Q&A. Operator?

Gracia Mahoney analyst
#6

Gracia here, sitting in for Travis. To kick things off, it seems like subscription revenues partially offset some of the upside you saw on product revenues this quarter. So I'd like to check whether there's anything worth flagging and any shift in expectations compared with 3 months ago, and how that pattern shaped any — you're only lifting the low end of the full-year guide while the high end stays the same, and how might the new algorithm updates play into that outlook for Q4 and into '27?

Scott Blumberg executive
#7

Thanks, Gracia. Yes, we experienced considerable strength in product margin. That came from the same-store growth driver. We posted record usage and growth in new utilization per account, which showed up in the product revenue line. Nothing really shifts as we move forward. We still anticipate most of our revenue coming from product, but we continue to view subscription as a durable long-term growth driver.

Henry Walker Householter analyst
#8

This is Henry, in for Robbie. I just wanted to dig a little deeper on delirium. And I was wondering, could you speak to any shifts in the commercial strategy you may be planning now that delirium is here — perhaps regarding adding new accounts versus deepening existing ones? And maybe on the OpEx side as well. In the press release, you flagged some higher infrastructure costs ahead of that launch. So how should we think about expenses going forward tied to this launch?

Xingjuan Chao executive
#9

Yes; we see delirium driving both utilization and also speeding up new account acquisition. More near term, potentially, especially in 2027, we'll see much more coming from utilization growth, since it is quicker to turn our existing accounts to start using delirium — in the pilot, we saw a very meaningful utilization increase. However, over the longer term, we also anticipate more and more of our new accounts will start with seizure and delirium together. So the account would launch at a higher usage or higher revenue; on OpEx, it's very important for us to emphasize that the delirium launch would be leveraging our existing sales team, both our current CAMs and TMs. And they — let's take CAM as an example, they already have very strong relationships with the ICU. They know the stakeholder. They go to the sites anyway. So not only can we leverage the existing sales force, there is a big synergy between seizure and delirium as well. As we see the accounts grow in the commercial pilot, we see it's a growth of both seizure awareness as well as delirium-related patient expansion.

Brandon Vazquez analyst
#10

Jane, you brought up — and I believe the press release said this as well — that same-store growth hit double digits for the quarter in utilization, and that it ranked among the strongest figures you've recorded since the IPO. Could you take a minute to walk us through that? First, maybe shed a little more light on the same-store metric. I think those of us on the Street use a utilization metric that's somewhat different. How is it defined on your end? And second, what's behind it? Are you already seeing benefits from pediatrics, which is now in its first full quarter of launch?

Xingjuan Chao executive
#11

Thanks, Brandon. I'll take your question on same-store growth; and when it comes to how the different metrics are defined, Scott may be able to help cover that. What I'd say is that this really reflects continuous execution of the playbook we put in place roughly 18 months ago. We went through a very thorough process of a series of commercial pilots, and we became very focused on 3 drivers — departmental expansion, meaning both expanding into additional ICUs as well as the ED, and physician engagement and protocolization. So we've really just kept building the team — an amazing team is in place — and kept executing. In particular, department expansion is accelerating, as I mentioned. We began focusing on the emergency department last year, and we're starting to see very strong buy-in from the ED as we meaningfully optimize patient flow there. As for pediatric and neonate, as Scott said on the call, it's still a bit too early, because we now have close to 750 accounts. Even though we launched — sorry, pediatric and NICU a few months ago, it will still take some time, since our installed base is so big.

Scott Blumberg executive
#12

Now regarding how we define that metric—we operate the business and gather utilization data, and because our device is cloud-enabled, we know exactly when it's in use, along with plenty of other information about usage patterns; that's the way we keep tabs on the business. It's also how we incentivize the team. That figure hit a record high. Purchases came in slightly below usage this quarter. That isn't something we try to manage. Our view is that over the long term, utilization is the key metric, and this quarter it reached a record high.

Xingjuan Chao executive
#13

Apologies — perhaps I should mention one additional point regarding same-store growth tied to department expansion, which is picking up speed. What we observe as well is that this kind of usage proves even more durable and sustainable, since once you're inside the department, with each year as you launch during a different part of the year, you're only capturing partial revenue there. So it isn't simply, oh, we saw usage growth there — we actually know the driver and KPI precisely, which gives us even greater confidence that this trend will carry on.

Bill Plovanic analyst
#14

Can you hear me okay?

Xingjuan Chao executive
#15

Yes.

Bill Plovanic analyst
#16

Alright. I'd like to focus on just one thing, delirium. I was hoping you might be able to help put some numbers around it for us — like, how far did the pilot actually go? How long do you figure it'll take before it's rolled out across all of your accounts? And what kind of utilization gains showed up in the pilot? Is that a 25% increase, a 50% increase? I mean, is it — or 100% increase? How should we frame the impact and then the timeline for that impact?

Xingjuan Chao executive
#17

Thanks, Bill. Quantifying those very important questions you've raised is a bit too early for us, since we are just launching delirium as we speak. That said, as we get close to guiding 2027, we should be in a position to offer more granular guidance there.

Jayson Bedford analyst
#18

Congratulations on the progress. Perhaps just to build on what Bill asked. Regarding the delirium pilot, you said you're seeing substantial gains in headband utilization. I was somewhat unsure. Do you mean only delirium? Or are you also seeing pull-through into greater utilization in seizure? And my second question concerns the delirium software rollout. Are there minimum volume commitments associated with this program?

Xingjuan Chao executive
#19

Yes. From a clinical standpoint, separating seizure from delirium is quite hard, particularly in the ICU or on the floor, and ICU is our primary target for launching delirium; so every one of our commercial pilot sites was in the ICU. What we observed — so for all these patients, physicians monitor ICU and — sorry, seizure and delirium together; so it's very challenging for us to distinguish them. That said, we've seen several drivers at the sites. We saw patient expansion. For instance, many sites weren't monitoring sepsis patients solely for seizure. And since seizure and delirium go together, they begin monitoring sepsis patients or other patient populations; we also observed growth among existing patients, and our hypothesis there was that we had more face time with physicians and the nursing team. So we're further raising awareness not only of delirium but of seizure as well. So we believe we're driving usage of seizure and delirium jointly. Again, it's a combined monitor. We don't truly separate them.

Scott Blumberg executive
#20

Yes. On the commitments front, we are building out workflows and collaborating with customers to make sure they're positioned for success, and that's what proved effective in the pilot — it's producing a material impact. When it comes to a contractual obligation on volumes, we aren't requiring one; however, the level of consistency in usage patterns during the pilot gives us strong conviction that if customers more or less follow the playbook here and engage with our customers, we'll see the usage impact.

Josh Jennings analyst
#21

Hey, this is Brian calling in for Josh. I’d like to ask something about the VA. You mentioned that you’ve locked in a commitment to expand further within the VA. Do you anticipate year-over-year growth in VA account additions during 2027 versus this year? Also, is there anything you can tell us about the utilization growth you’ve observed so far across VA accounts?

Scott Blumberg executive
#22

Yeah. I’ll take the volume part; the VA operates on a fairly strict September fiscal year-end calendar. So that commitment was obtained near the close of the last fiscal year, for the fiscal year now beginning. The commitment’s size is roughly consistent with what we saw a year ago. As a result, we’d expect those to be added into the account base across the next 2 to 3 quarters or so. We’re present in a meaningful number of VAs, and we’re still — even once we launch these accounts in the minorities, there’s plenty of headroom for growth.

Xingjuan Chao executive
#23

When it comes to VA usage, we don't put a specific number on individual hospital systems. That said, broadly speaking, with the top-down launches we observed earlier, utilization tends to run somewhat below what we see in our typical average account. But as we build more experience, and as our customers build more experience as well, we do see growth as we bring on more and more VA accounts. As we keep gaining that experience, we're confident we'll keep driving not only entry into more VAs but also sustainable usage within those accounts.

Marie Thibault analyst
#24

What I mainly want to get a handle on is where sales growth and expense growth could be going. I'm not after 2027 guidance — I just want a clearer picture of when we could begin seeing an inflection from those territory managers you brought on, since you started adding them a couple of years ago, and whether we should anticipate stepped-up investments as you head into the delirium launch and keep going with neonatal and pediatrics. So really, just a clearer sense of the trends from here.

Scott Blumberg executive
#25

This year we put money into things that genuinely feed our growth drivers for 2027, and that covers the strategic account management infrastructure for the regional health systems, delirium included. So when it comes to the infrastructure we have in place, we've by and large already made the investments for what sits ahead of us. We watch our infrastructure spending decisions very carefully — sales, R&D, and elsewhere — to make sure they line up with our North Star, which is reaching breakeven with the cash we have on hand. That being said, we look at the latest facts each quarter and base investment choices on the most current and relevant information. So the short answer: we feel really good about the infrastructure we've got, and we'll be watching the business closely — especially how delirium performs over the coming months — and we'll make the right call with the right information.

Jeffrey Cohen analyst
#26

I was hoping you might say a bit more about the delirium pilot involving seizure; and could you also discuss what you've learned on the clinical workflow side and perhaps how that ties into some of the guidance the societies currently have out there?

Xingjuan Chao executive
#27

Let me just confirm I've got your question right — you're asking about the workflow around seizure and delirium, and how the guideline — how — what guidelines already exist to steer the use of seizure and delirium monitoring?

Jeffrey Cohen analyst
#28

Yes, and how that might shift.

Xingjuan Chao executive
#29

Yes. Right now, the existing guidance is fairly siloed in how it advises triaging and monitoring seizures and managing them, as opposed to how it detects and handles delirium. But — that's precisely why, when we launch these accounts, we frequently step in and combine those guidelines. The point is more about making patients aware of these guidelines. Take sepsis patients as my example: plenty of clinical evidence papers demonstrate that among sepsis patients, roughly 10% to 15% of them, if their mental status is altered in the ICU, would experience seizures; and then around 60%, 6 to 0 percent of sepsis patients would develop delirium; and right after a seizure, a patient could go on to develop delirium; and the symptoms of seizure and delirium are also quite alike. So taken all together, it becomes very hard for the bedside nurse and physicians to determine both, is the patient seizing or having delirium? Also, once you begin the management pathway for seizure and delirium, are you on the correct track? That is exactly where our device comes in; and we can clearly — for instance, the case study I shared during the earnings call, this woman in her 30s with septic shock, she could be having a seizure. But our device says, no, the patient is having delirium, so manage your delirium, which led to the medication review of cefepime. You could see a very similar presentation in a patient, but the device might come back and say, no, the patient is seizing, and that would entirely alter the course — that would treat patients with anti-seizure medication rather than medication review. So those are some examples of the workflow. Obviously, we don't design the workflow for the hospital. We instead share other hospitals' workflows and the existing guidelines to support our customers.

Xingjuan Chao executive
#30

Thanks, everybody, for being on this call. We feel a lot of excitement and pride about everything we got done in Q3, and we're just as excited about what's coming next. We look forward to sharing additional good news as we move ahead.

Operator operator
#31

This concludes today's meeting. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete CeriBell, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to CeriBell, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.